R. Altaha, E. Crowell, G. Hobbs, G. Higa, and J. Abraham, Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma, Cancer, vol.4, issue.3, pp.442-443, 2005.
DOI : 10.1002/cncr.20813

T. Chua and N. Merrett, Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review, International Journal of Cancer, vol.56, issue.12, pp.2845-2856, 2012.
DOI : 10.1002/ijc.26292

Y. Bang, C. Van, A. Feyereislova, H. Chung, L. Shen et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, The Lancet, vol.376, issue.9742, pp.687-697, 2010.
DOI : 10.1016/S0140-6736(10)61121-X

J. Ruschoff, W. Hanna, M. Bilous, M. Hofmann, R. Osamura et al., HER2 testing in gastric cancer: a practical approach, Modern Pathology, vol.57, issue.5, pp.637-650, 2012.
DOI : 10.1038/modpathol.2011.198

H. Grabsch, S. Sivakumar, S. Gray, H. Gabbert, and W. Muller, HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value -conclusions from 924 cases of two independent series, Cell Oncol, vol.32, pp.57-65, 2010.

A. Minisini, S. Moroso, L. Gerratana, M. Giangreco, D. Iacono et al., Risk factors and survival outcomes in patients with brain metastases from breast cancer, Clinical & Experimental Metastasis, vol.112, issue.8, pp.951-956, 2013.
DOI : 10.1007/s10585-013-9594-5

H. Ahn, Y. Park, S. Lee, S. Park, C. Maeng et al., Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes, SpringerPlus, vol.362, issue.12, p.136, 2013.
DOI : 10.1056/NEJMct0806951